Status:
UNKNOWN
Buccodental Manifestations in Patients With Acromegaly
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Acromegaly
Eligibility:
All Genders
18-90 years
Brief Summary
Context: Acromegaly is the rare condition (3 to 4 new cases per million per year) due to Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting in Insulin Growth Factor 1 (IG...
Detailed Description
Context/ study relevance: Acromegaly is a rare condition (3 to 4 new cases per million per year) due to Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting in Insulin Grow...
Eligibility Criteria
Inclusion
- Adult acromegal patient followed in the endocrinology/diabetology service of the CHU of Clermont-Ferrand
- Proven diagnosis of acromegaly or previous acromegaly
Exclusion
- Minor subject
- Subject under guardianship or curatorship
- Total toothless patients
- No possibility of written informed consent
- Medical or chirurgical conditions interacting with oral health so that the oral evaluation is not reliable
- Medication associated with gingival hypertrophy
Key Trial Info
Start Date :
December 15 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2019
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03401008
Start Date
December 15 2016
End Date
March 30 2019
Last Update
January 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003